Lindsey Shapiro, PhD, science writer —

The investigational oral therapy APT-101 was well tolerated and reduced fibrosis, or scarring, in a mouse model of systemic sclerosis (SSc), according to a recent presentation from the therapy’s developer, Apie Therapeutics. Apie is developing APT-101 to treat interstitial lung disease (ILD), a term that encompasses a group…

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to efzofitimod (ATYR1923) to treat interstitial lung disease (ILD) in people with systemic sclerosis (SSc). The therapy was developed by aTyr Pharma for treating severe diseases affecting the lungs. Efzofitimod was designated as an orphan drug…

Several clinical characteristics in people with systemic sclerosis (SSc) — specifically, being male, older age, diffuse SSc forms, and inflammation — were associated with a greater accumulation of organ damage over time in a recent study. The level of damage accumulation, called a damage trajectory, also correlated with mortality…

New data from patient samples and a mouse model provide support for the further development of Chemomab Therapeutics‘ lead candidate, CM-101 — an antibody targeting the CCL24 protein — for the treatment of systemic sclerosis (SSc), according to two recent scientific presentations. Encouraged by the new data, the company…

Nailfold videocapillaroscopy (NVC), a technique to detect small changes in circulation, may be a promising biomarker of likely severe organ involvement in people with systemic sclerosis (SSc) although more data is needed, according to a recent study. “The generation of consistent high-quality research in this area may lead to…

Low muscle mass is associated with gastrointestinal (GI) bloating in patients with systemic sclerosis (SSc), a recent study revealed. Disease duration, severity, and activity, as well as skin thickening, also were higher in patients with low muscle mass. “At the best of our knowledge, this is the first study…

Shorter telomeres — the protective ends on chromosomes and a marker of aging — were observed in people with systemic sclerosis (SSc), particularly among those with lung fibrosis (scarring) or anti-topoisomerase-I autoantibodies (ATA), according to a recent study. In a mouse model of scleroderma, treatment with GSE4 —…

Levels of the protein, galectin-3, are associated with heart involvement in people with systemic sclerosis (SSc), according to a recent pilot study. The protein could be used as a biomarker to more quickly detect and address cardiac problems. Another protein, called soluble suppression of tumorigenicity-2 (sST2), was…

The U.S. Food and Drug Administration (FDA) has approved a clinical trial to determine the safety and efficacy of adipose-derived regenerative cells (ADRCs) for the treatment of hand dysfunction in patients with diffuse cutaneous scleroderma, Paracrine has announced. The Phase 3 trial, called STAR…

Several risk factors for diastolic dysfunction (DD), the heart’s inability to fill with blood properly after it beats, were identified in people with systemic sclerosis (SSc) in a recent study. These risk factors, such as obesity, could be potentially modified to reduce the occurrence of more serious disease outcomes,…